| Literature DB >> 28588623 |
Hyun Nam1,2,3, Gee-Hye Kim4, Yoon-Kyung Bae2,3,5, Da-Eun Jeong2,3,5, Kyeung-Min Joo2,3,5,6, Kyunghoon Lee3,6,7, Sun-Ho Lee1,2,5.
Abstract
Previously, the perivascular characteristics of dental pulp stem cells (DPSCs) were reported, which suggested the potential application of DPSCs as perivascular cell source. In this study, we investigated whether DPSCs had angiogenic capacity by coinjection with human umbilical vein endothelial cells (HUVECs) in vivo; in addition, we determined the role of stromal cell-derived factor 1-α (SDF-1α) and C-X-C chemokine receptor type 4 (CXCR4) axis in the mutual interaction between DPSCs and HUVECs. Primarily isolated DPSCs showed mesenchymal stem cell- (MSC-) like characteristics. Moreover, DPSCs expressed perivascular markers such as NG2, α-smooth muscle actin (α-SMA), platelet-derived growth factor receptor β (PDGFRβ), and CD146. In vivo angiogenic capacity of DPSCs was demonstrated by in vivo Matrigel plug assay. We could observe microvessel-like structures in the coinjection of DPSCs and HUVECs at 7 days postinjection. To block SDF-1α and CXCR4 axis between DPSCs and HUVECs, AMD3100, a CXCR4 antagonist, was added into Matrigel plug. No significant microvessel-like structures were observed at 7 days postinjection. In conclusion, DPSCs have perivascular characteristics that contribute to in vivo angiogenesis. The findings of this study have potential applications in neovascularization of engineered tissues and vascular diseases.Entities:
Year: 2017 PMID: 28588623 PMCID: PMC5447288 DOI: 10.1155/2017/8085462
Source DB: PubMed Journal: Stem Cells Int Impact factor: 5.443
Figure 1Primary isolation and characterization of DPSCs. Primary isolated DPSCs were cultured and characterized. (a) DPSCs showed typical MSC-like morphology at passage 3. (b) The expression of surface antigens was determined by FACS analysis. DPSCs were positive for MSC markers (CD29, CD44, CD73, CD90, and CD105) but negative for hematopoietic cell markers (CD14, CD34, CD45, CD117, and HLA-DR) and endothelial cell marker (CD31). DPSCs were induced in osteogenic or adipogenic medium for 21 days. (c) Alizarin red staining revealed deposits of calcium. (d) Oil red O staining showed lipid vacuoles. (e) Alcian blue staining confirmed chondrogenic differentiation.
Figure 2The expression of perivascular markers in DPSCs. The expression of perivascular markers in three different lines of DPSCs was determined by qPCR and FACS analysis. (a) DPSCs expressed NG2, α-SMA, PDGFRβ, and CD146. Arbitrary unit in y-axis represented 2−∆CT × 104. (b) In the results by FACS analysis, DPSCs expressed NG2, PDGFRβ, and CD146. However, the expression of NG2 was subdivided into NG2-positive and NG2-negative populations dependent on the lines of DPSCs. The expression of CD146 was broadly distributed. One of representative pieces of data was shown.
Figure 3In vivo angiogenic potential of DPSCs. To investigate in vivo angiogenic potential of DPSCs, Matrigel plug assay was conducted. DPSCs and HUVECs were subcutaneously injected and separated or together into immunodeficient mice. At 7 days postinjection, Matrigel plug was removed and analyzed by H&E and immunofluorescent stainings. (a) In the results of DPSCs alone or HUVEC alone, no obvious microvessel-like structures were observed. However, when DPSCs and HUVECs were coinjected, microvessel-like structures were formed and red blood cells were observed in the lumen. (b) Immunofluorescent staining by CD31 and α-SMA showed that microvessel-like structures were stained on coinjection with DPSCs and HUVECs subcutaneously.
Figure 4The involvement of SDF-1α and CXCR4 axis in in vivo angiogenesis by DPSCs and HUVECs. The expression of angiogenic factors and receptors was verified by qPCR. (a) The expression of SDF-1α, PDGFRβ, and VEGF was higher in DPSCs than that in HUVECs. On the contrary, the expression of CXCR4, PDGF-BB, VEGFR1, and VEGFR2 was higher in HUVECs than that in DPSCs. ∗p < 0.05. (b) To confirm the functional involvement of SDF-1α and CXCR4 axis in in vivo angiogenesis, AMD3100, an antagonist of CXCR4, was mixed with Matrigel plug. At 7 days postinjection, there were no microvessel-like structures in the AMD3100-treated group as compared to control group.